Previous 10 | Next 10 |
Regeneron Pharmaceuticals, Inc. (REGN) SVB Securities Global Biopharma Conference February 14, 2023 09:20 AM ET Company Participants Ryan Crowe - VP, IR Izzy Lowy - SVP of Clinical Development for Oncology Andres Sirulnik - SVP, Translational & Clinical Sciences, H...
Although equities started the year on a strong note, investors haven't forgotten that we experienced a bear market last year. And even after the recent run, the S&P 500 remains down by nearly double-digits over the trailing-12-month period. Even so, some companies have done just fine ...
Summary Regeneron’s core business keeps growing at double-digit rate. Dupixent continues to be a major driver of business growth, with COPD treatment data in the spotlight. A key moment for Eylea’s sales dynamic is the possible approval of the higher dosage regime in A...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips When markets closed last month, it became official: Cathie Wood’s ARK Innovation ETF (NYSEARCA: ARKK ) had scored its best-returning month in its 9-year history. The 27.8% return in January was a welcome reversal...
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) are each up about 20% over the past year. The biotech companies have shown increased revenue and earnings per share (EPS) over the past three years and have burgeoning pipelines that s...
Regeneron Pharmaceuticals ( NASDAQ: REGN ) has received FDA approval for its blockbuster eye therapy Eylea to treat preterm infants with retinopathy of prematurity (ROP), a leading cause of childhood blindness. ROP is a rare eye disease that mainly affects infants who are born b...
ROP is a leading cause of childhood blindness worldwide EYLEA now approved to treat five retinal conditions caused by ocular angiogenesis TARRYTOWN, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Adm...
Summary As discussions about the trillion-dollar debt ceiling question intensify on Capitol Hill, we bring you one of our budget-spending-oriented trading strategies. While the largest and most unique government contracts catch media outlets' attention, most contracts end up being out o...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developme...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...